tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Jonathan Wolleben, 339 are a BUY (99.71%), 1 are a HOLD (0.29%).
Analyst Jonathan Wolleben, carries an average stock price target met ratio of 37.91% that have a potential upside of 48.95% achieved within 200 days.
Jonathan Wolleben’s has documented 659 price targets and ratings displayed on 24 stocks. The coverage was on Healthcare, Communication Services sectors.
Most recent stock forecast was given on SGMT, Sagimet Biosciences at 01-Oct-2026.
Analyst best performing recommendations are on DBVT (DBV TECHNOLOGIES).
The best stock recommendation documented was for RYTM (RHYTHM PHARMACEUTICALS) at 7/2/2025. The price target of $84 was fulfilled within 7 days with a profit of $17.08 (25.52%) receiving and performance score of 36.46.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 28-Jul-2020
$11
$8.88 (418.87%)
$11
4 months 24 days ago
(02-Jun-2026)
0/19 (0%)
$8.1 (279.31%)
Buy Since 02-Jun-2021
$20
$17.88 (843.40%)
$17.33
5 months 7 days ago
(19-May-2026)
0/24 (0%)
$17.26 (629.93%)
Buy Since 29-Dec-2021
$28
$25.88 (1220.75%)
$35
6 months 29 days ago
(27-Mar-2026)
0/5 (0%)
$24.98 (827.15%)
Buy Since 25-Sep-2020
$18
$15.18 (538.30%)
$20
1 years 2 months 13 days ago
(13-Aug-2025)
3/14 (21.43%)
$14.26 (381.28%)
272
Buy Since 12-Nov-2024
$24
$21.18 (751.06%)
$26
1 years 2 months 13 days ago
(13-Aug-2025)
0/3 (0%)
$20.26 (541.71%)
Which stock is Jonathan Wolleben most bullish on?
Which stock is Jonathan Wolleben most reserved on?
